Literature DB >> 18535592

Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage.

P G Costa1, F P Saraiva, I C Pereira, M L R Monteiro, S Matayoshi.   

Abstract

AIM: To compare morphometric data of the eyelid fissure and the levator muscle function (LF) before and up to 6 months after transcutaneous injection with five units of Botox in patients with upper lid retraction (ULR) from congestive or fibrotic thyroid eye disease (TED).
METHODS: Twenty-four patients with ULR from TED were submitted to transcutaneous injection of 5 units (0.1 ml) of Botox in one eye only. Patients were divided into two groups: 12 with congestive-stage TED (CG), and 12 with fibrotic-stage TED (FG). Bilateral lid fissure measurements using digital imaging and computer-aided analysis were taken at baseline and at regular intervals 2 weeks, 1 month, 3 months and 6 months after unilateral Botox injection. Mean values taken at different follow-up points were compared for the two groups.
RESULTS: Most patients experienced marked improvement in ULR, with a mean reduction of 3.81 mm in FG and 3.05 mm in CG. The upper eyelid margin reflex distance, fissure height and total area of exposed interpalpebral fissure were significantly smaller during 1 month in CG and during 3 months in FG. Reduction in LF and in the difference between lateral and medial lid fissure measurements was observed in both groups. The treatment lasted significantly longer in FG than in CG.
CONCLUSIONS: A single 5-unit Botox injection improved ULR, reduced LF and produced an adequate lid contour in patients with congestive or fibrotic TED. The effect lasts longer in patients with fibrotic orbitopathy than in patients with congestive orbitopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535592     DOI: 10.1038/eye.2008.165

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  8 in total

Review 1.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

2.  Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy.

Authors:  Dong-Dong Xu; Yu Chen; Hai-Yan Xu; Hui Li; Zhu-Hua Zhang; Yu-Hua Liu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

3.  Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections.

Authors:  Sung Jun Lee; Tyler Hyung Taek Rim; Sun Young Jang; Chan Yun Kim; Dong Yeob Shin; Eun Jig Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-12       Impact factor: 3.117

4.  [Management of moderate and severe dysthyroid orbitopathy: about 22 cases].

Authors:  Nadia Daldoul; Leila Knani; Faten Gatfaoui; Hechmi Mahjoub
Journal:  Pan Afr Med J       Date:  2017-08-07

5.  Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction.

Authors:  Mahaa Hassan Hussien; Elham Abd El-Wahed Hassan; Nermien Salah El-Dien Mohammed El-Haddad
Journal:  Ther Adv Ophthalmol       Date:  2020-12-28

Review 6.  Management of eyelid retraction related to thyroid eye disease.

Authors:  Tammy H Osaki; Lucas G Monteiro; Midori H Osaki
Journal:  Taiwan J Ophthalmol       Date:  2022-02-14

7.  Bovine Acellular Dermal Matrix for Levator Lengthening in Thyroid-Related Upper-Eyelid Retraction.

Authors:  Jing Sun; Xingtong Liu; Yidan Zhang; Yazhuo Huang; Sisi Zhong; Sijie Fang; Ai Zhuang; Yinwei Li; Huifang Zhou; Xianqun Fan
Journal:  Med Sci Monit       Date:  2018-05-02

Review 8.  Safety of Aesthetic Medicine Procedures in Patients with Autoimmune Thyroid Disease: A Literature Review.

Authors:  Kamil Adamczyk; Ewa Rusyan; Edward Franek
Journal:  Medicina (Kaunas)       Date:  2021-12-24       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.